Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-674.81%
operating margin TTM
-759.73%
revenue TTM
106.02 Million
revenue per share TTM
1.34$
valuation ratios | |
|---|---|
| pe ratio | -20.12 |
| peg ratio | 5.82 |
| price to book ratio | 6.27 |
| price to sales ratio | 122.78 |
| enterprise value multiple | -18.88 |
| price fair value | 6.27 |
profitability ratios | |
|---|---|
| gross profit margin | -74.18% |
| operating profit margin | -759.73% |
| pretax profit margin | -674.81% |
| net profit margin | -674.81% |
| return on assets | -26.78% |
| return on equity | -33.35% |
| return on capital employed | -32.24% |
liquidity ratios | |
|---|---|
| current ratio | 7.38 |
| quick ratio | 7.38 |
| cash ratio | 1.58 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 26.38 |
| cash conversion cycle | -26.38 |
| receivables turnover | 0.00 |
| payables turnover | 13.84 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | 0.09 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.08 |
| interest coverage | -1,390.21 |
| cash flow to debt ratio | -2.71 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.64 |
| cash per share | 5.79 |
| operating cash flow per share | -2.61 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -2.71 |
| short term coverage ratios | -16.59 |
| capital expenditure coverage ratio | -100.01 |
Frequently Asked Questions
When was the last time Kymera Therapeutics, Inc. (NASDAQ:KYMR) reported earnings?
Kymera Therapeutics, Inc. (KYMR) published its most recent earnings results on 04-11-2025.
What is Kymera Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Kymera Therapeutics, Inc. (NASDAQ:KYMR)'s trailing twelve months ROE is -33.35%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Kymera Therapeutics, Inc. (KYMR) currently has a ROA of -26.78%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did KYMR's net profit margin stand at?
KYMR reported a profit margin of -674.81% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is KYMR's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.38 in the most recent quarter. The quick ratio stood at 7.38, with a Debt/Eq ratio of 0.09.